BIOHARVEST SCIENCES Q1 HIGHLIGHTS REPORT

February 14, 2022

Dear subscriber,

We have started 2022 with several very positive news releases, including issuing guidance that 2022 revenues will increase 2.5x- 3.5x as we expand both our nutraceutical and cannabis sales. There is an aggressive communication plan to increase our exposure in the biotechnology ecosystem, and this newsletter summarizes some of the active Q1 initiatives to educate both investors and future partners on the BioHarvest platform.

Q1 Industry Conferences

_______________________________________________________________________________________________________________

Feb 9, 2022: CEO Ilan Sobel presented this week at the Money Show Cannabis Investing Conference. Over 300 investors participated in our session, and we welcome these new investors to the BioHarvest Community. The Presentation can be viewed here

 

 

Feb 14-17, 2022: BioHarvest is a presenting sponsor at the Biotechnology Innovation Organization (BIO)  CEO and Investor Conference, a hybrid virtual/live event in NYC. This conference is a networking and investment event for major global biotech and investment leaders.

 

March 1-2, 2022: 15th Annual European Life Sciences CEO Forum for Partnering & Investment. Ilan Sobel will be presenting, and will participate in a “BioTech meets Foodtech” panel.

 

_______________________________________________________________________________________________________________

BioHarvest in the News

Our Top 2022 News Releases thru February 14, 2022

Jan 6, 2022: BIOHARVEST SCIENCES REPORTS DOUBLE-DIGIT Q4 SALES ORDERS GROWTH IN FIRST FULL YEAR OF VINIA SALES

• 485% year-over-year growth with total sales orders of USD 2.4M in 2021

 

Jan 20, 2022: BIOHARVEST SCIENCES INC. PLANS TO BUILD A PRODUCTION FACILITY IN ONTARIO TO SERVE THE CANADIAN MARKET WITH UNIQUE CANNABIS PRODUCTS

• Announced that production of full-spectrum Cannabis biomass has been moved to industrial scale bioreactors

 

Jan 26, 2022: BIOHARVEST SCIENCES INC. PROJECTS 2022 REVENUE TO GROW 2.5X-3.5X TO A RANGE OF USD $5M-$7M

• 2022 Revenue will include sales of VINIA® and Cannabis, both with high gross margins

 

Feb 10, 2022:  BIOHARVEST SCIENCES INC. ENGAGES THUNDER11 AS A PUBLIC RELATIONS AGENCY OF RECORD

• Award winning New York based communication firm specializes in technology and health care

_______________________________________________________________________________________________________________

Media Coverage

A lively Podcast discussion with Doc Rob, “the Concierge for Better Living”. Listen to the Interview.

 

 

Ilan sat down for a “Power Play” interview to discuss our unique platform and disruptive 2022 plans Watch Video

 

“A Post Plant Future?” Feature article on BioHarvest Sciences (page 42-43). Read Article

_______________________________________________________________________________________________________________

Want to Learn More?

If you are interested in joining a small group call with our team, we conduct weekly “Coffee With Ilan” sessions, hosted by CEO Ilan Sobel, every Wednesday at 11 am PST. These are casual Q+A Zoom calls limited to 3 invitees per call. If you are interested in participating in a session, please contact justin@bioharvest.com for details.

Your feedback and support are critical to our growth as a biotechnology leader – if you are inspired and energized by our progress, please share our news with your network and help take us to the next level in 2022!

Our Blog

2024 CEO Letter to Shareholders

“Our goal is to accelerate the Botanical Synthesis movement that our team has wholly dedicated themselves to – driving forward innovation, our...

Read More

About BioHarvest Sciences Inc.

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at industrial scale, without the need to grow the plant itself. BioHarvest is currently focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions, within two major business verticals – nutraceutical health and wellness products such as dietary supplements, and development of plant cell-based Active Pharmaceutical Ingredients (API’s) that focus on specific medical indications.

ABOUT BIOHARVEST SCIENCES INC.